作者：
Harriet M,Kluger [1]
;
Hussein A,Tawbi [2]
;
Maria L,Ascierto [3]
;
Michaela,Bowden [4]
;
Margaret K,Callahan [5]
;
Edward,Cha [6]
;
Helen X,Chen [7]
;
Charles G,Drake [8]
;
David M,Feltquate [4]
;
Robert L,Ferris [9]
;
James L,Gulley [7]
;
Shilpa,Gupta [10]
;
Rachel W,Humphrey [11]
;
Theresa M,LaVallee [12]
;
Dung T,Le [13]
;
Vanessa M,Hubbard-Lucey [14]
;
Vassiliki A,Papadimitrakopoulou [2]
;
Michael A,Postow [5]
;
Eric H,Rubin [15]
;
Elad,Sharon [7]
;
Janis M,Taube [16]
;
Suzanne L,Topalian [13]
;
Roberta,Zappasodi [5]
;
Mario,Sznol [1]
;
Ryan J,Sullivan [17]
作者单位：
Yale School of Medicine, New Haven, CT, United States.
[1]
MD Anderson Cancer Center, Houston, TX, United States.
[2]
AstraZeneca, London, United Kingdom.
[3]
Bristol-Meyers Squibb, New York, NY, United States.
[4]
Memorial Sloan Kettering Cancer Center, New York, NY, United States.
[5]
Genentech, San Francisco, CA, United States.
[6]
National Cancer Institute, Bethesda, MD, United States.
[7]
Columbia University Medical Center, New York, NY, United States.
[8]
UPMC Hillman Cancer Center, Pittsburgh, PA, United States.
[9]
Cleavland Clinic, Cleveland, OH, United States.
[10]
CytomX Therapeutics, San Francisco, CA, United States.
[11]
Parker Institute for Cancer Immunotherapy, San Francisco, CA, United States.
[12]
John Hopkins University, Baltimore, MD, United States.
[13]
Cancer Research Institute, New York, NY, United States.
[14]
Merck & Co, Kenilworth, NJ, United States.
[15]
John Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, MD, United States.
[16]
Massachusetts General Hospital, Boston, MA, United States rsullivan7@mgh.harvard.edu.
[17]
DOI
10.1136/jitc-2019-000398
PMID
32238470
发布时间
2024-03-28
换一批
换一批
